Quantification of Glucagon-Like Peptide-1 Agonist Tirzepatide Using an Agilent 6495D Triple Quadrupole LC/MS System

Significance of Topic

Peptide therapeutics such as the GLP-1 receptor agonist tirzepatide play a critical role in treating type 2 diabetes and obesity. Monitoring peptide integrity during manufacturing and storage is essential because chemical modifications can impact safety and efficacy. Highly sensitive and robust quantitative methods are therefore indispensable in biopharmaceutical development and quality control.

Objectives and Study Overview

This study aimed to develop a rapid and precise multiple reaction monitoring (MRM)-based LC/MS method for quantifying both unmodified (native) and mono-oxidized tirzepatide. Key goals included establishing limits of quantitation (LOQs), assessing dynamic range, and evaluating accuracy and precision for stability testing and impurity profiling.

Methodology and Instrumentation

Sample Preparation:

• Tirzepatide dissolved at 1.0 mg/mL in methanol and serially diluted (0.025–250 ng/mL) in 30% ACN with 2% DFA for calibration; QC samples at 0.75, 7.5, and 75 ng/mL.
• Mono-oxidized form generated by incubating 0.5 mg/mL peptide in 30% ACN with 2% H₂O₂ overnight.

Chromatography and Mass Spectrometry:

• Agilent AdvanceBio Peptide Mapping column (2.1×150 mm, 2.7 µm) with an 8-minute gradient (0.1% DFA in water/ACN).
• Agilent 6495D triple quadrupole LC/MS with Jet Stream ESI source, positive mode, optimized gas and voltage settings.
• MRM transitions selected from [M+5H]⁵⁺ precursor ions at m/z 1,204.4 (native) and 1,208.1 (oxidized), monitoring the y₄ fragment at m/z 396.3.

Key Results and Discussion

The native tirzepatide method exhibited a linear range of 0.025–250 ng/mL (R²=0.997) with LOQ at 0.025 ng/mL, while the oxidized form ranged 0.25–250 ng/mL (R²=0.996) with LOQ at 0.25 ng/mL. Retention times were 4.0 min (native) and 3.9 min (oxidized). Precision (%CV) remained below 6% across all levels, and accuracy ranged from 81 % to 118 %, meeting regulatory criteria.

Benefits and Practical Applications

The method delivers rapid 8-minute runs, high sensitivity for low-level detection, and reproducible quantitation of peptide drug and degradation products. It is well suited for stability studies, batch release testing, and impurity characterization in peptide drug development.

Future Trends and Applications

Expanding this MRM-based approach to multi-peptide panels could support simultaneous quantitation of diverse biotherapeutics. Integration with automated sample preparation and high-throughput screening will accelerate early-stage development. Advanced data analytics may further enhance detection of complex post-translational modifications.

Conclusion

An Agilent 6495D triple quadrupole LC/MS workflow with MRM detection offers a fast, sensitive, and precise solution for quantifying native and oxidized tirzepatide. The validated method meets stringent performance criteria, making it a reliable tool for peptide therapeutic analysis.

Reference

• Müller T.D. et al. "Glucagon-Like Peptide 1 (GLP-1)." Mol. Metab. 30 (2019): 72–130.
• U.S. Food and Drug Administration. "FDA Approves New Medication for Chronic Weight Management," Nov. 8, 2023.
• Suresh Babu C.V. "Characterization of Forced Degradation Impurities of GLP-1 Agonists by LC/Q-TOF Mass Spectrometry," Agilent Technologies Application Note 5994-7794EN (2024).
• U.S. Food and Drug Administration. "Bioanalytical Method Validation Guidance for Industry," May 2018.